Ad­di­tion­al drug­mak­ers flag risks of work­ing with WuXi amid height­ened US scruti­ny

More drug com­pa­nies are dis­clos­ing the po­ten­tial for clin­i­cal tri­al de­lays and drug short­ages if the US gov­ern­ment black­lists a fam­i­ly of WuXi com­pa­nies used …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER